NCT07187856

Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus

A Phase 2 Randomised Controlled Study to Investigate the Efficacy and Safety of Subcutaneously Administered PG-102 for 24 Weeks Compared With Placebo and Open-Label Semaglutide in Patients With Type 2 Diabetes Mellitus

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: ProGen. Co., Ltd. · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus

Conditions

• Type 2 Diabetes Mellitus (T2DM)

Interventions

Type	Name	Description
DRUG	PG-102	PG-102 is administered subcutaneously once weekly with a titration regimen.
DRUG	Placebo	Placebo is administered subcutaneously once weekly.
DRUG	Semaglutide	Open-label semaglutide is administered subcutaneously once weekly with titration regimen.

Timeline

• Start date: 2026-01-01
• Primary completion: 2026-09-01
• Completion: 2026-12-01
• First posted: 2025-09-23
• Last updated: 2025-09-23

Locations

1 site across 1 country: Australia